Eli Lilly forecasts that its profit will fall by up to one-third this year, Reuters has reported. The drugmaker’s forecasted revenue for 2014 is now between $19.2 billion and $19.8 billion, with a net income of $3 billion and operating cash flow of $4 billion.
Eli Lilly forecasts that its profit will fall by up to one-third this year, Reuters has reported. The drugmaker’s forecasted revenue for 2014 is now between $19.2 billion and $19.8 billion, with a net income of $3 billion and operating cash flow of $4 billion.
The profit fall is in line with the company’s expectations, however, as Lilly will feel most sharply this year the effect of the patent cliff that began in October 2011 with the loss of U.S. patent protection for its schizophrenia treatment Zyprexa. At its peak Zyprexa had annual sales of more than $5 billion but now brings in $1 billion. This March the company’s osteoporosis drug Evista, with annual sales of $1 billion, will also be open to generic competion.
The company is now pinning its hopes on the experimental drug ramucirumab, which has been proven to prolong the survival of stomach cancer patients in late-stage clinical trials. Lilly Chief John Lechleiter also confirmed that diabetes drugs will remain “a company mainstay”. The company has two experimental diabetes drugs in late-stage trials, the injectable medicine dulaglutide and a basal insulin.
Atlantic Equities analyst Richard Purkiss told Reuters that he expects Lilly’s revenue to “bounce back strongly in 2015, and for the company to have mid-teens percentage growth in earnings from 2014 to 2017.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.